Rules/misleading presentation/US-MIS-003

Ad must not omit facts material to its representations or to use consequences

AI-verifiedblockerBinding lawRaised as a question — a person decides

Rule

An ad fails the true-statement standard if it omits facts material to its claims or to the consequences of using the drug as recommended.

Check

Identify claims and recommended use; assess whether any materially relevant fact (safety, limitation, condition) is omitted.

Escalate when

Materiality of an omitted fact is debatable.

Where this comes from

21 CFR 202.1(e)(5)(iii). The highlighted words are quoted exactly; a script confirms they appear in the source before the rule can be published.

…is information is not fairly balanced by a presentation of a summary of true information relating to side effects and contraindications of the drug; Provided, however, That no advertisement shall be considered to be in violation of this section if the presentation of true information relating to side effects and contraindications is comparable in depth and detail with the claims for effectiveness or safety. (iii) It fails to reveal facts material in the light of its representations or material with respect to consequences that may result from the use of the drug as recommended or suggested in the advertisement. (6) Advertisements that are false, lacking in fair balance, or otherwise misleading. An advertisement for a prescription drug is false, lacking in fair balance, or otherwise misleading, or otherwise violative of section 502(n) of the act, among other reasons, if it: (i) Contains a representation or suggestion, not approved or permitted for use in the labeling, that a drug is better, more effective, useful in a b…

Open the original at these words on ecfr.gov ↗Read our full copy →

Document: 21 CFR 202.1
Version: 2026-09-16 — the link above is pinned to this date, so it shows the text as it stood then
Retrieved: 2026-09-21 from www.ecfr.gov
Fingerprint: a542640a872b3f2702d549e8…

Applies when

Naturepromotional

How this rule was checked

Citation proven by script and passed an independent verifier running on a different model. Not yet confirmed by a human.

Drafted
claude-sonnet-5 · 2026-09-21
Independent verification — pass
claude-opus-5 · 2026-09-21
Reviewer's reasons
- The quote is operative regulatory text, not an example or commentary: it is one of the enumerated conditions in 21 CFR 202.1(e)(5) under which an advertisement 'does not satisfy the requirement that it present a "true statement" of information in brief summary relating to side effects, contraindications, and effectiveness.' The rule statement restates both prongs (material in light of representations; material as to consequences of recommended/suggested use) without addition.
- Not overstated: the provision is framed in mandatory failure terms ('does not satisfy the requirement ... if'), so rendering it as a failure condition matches the source. It is drawn from (e)(5), the definitional failure list, rather than from (e)(7)'s permissive 'may be false ... or otherwise misleading' list, so no 'may' has been hardened into 'is'.
- Scope is appropriate: the rule is phrased as applying to an 'ad', consistent with 202.1's reach over prescription drug advertisements, and (e)(3)(i) confirms the true-statement requirement 'applies to the entire advertisement,' so the promotional gate neither invents a limit nor omits an obvious one.
- Atomic: the two statutory prongs form a single materiality test resolved by one omission analysis, not separately dispositionable requirements.
- Determinism 'judgment' is correct — whether an omitted fact is 'material in the light of its representations' depends on the impression created by the ad's claims, not on a literal match or presence check. The escalation trigger for debatable materiality is consistent with this.
- Authority 'binding' is correct (codified federal regulation), and severity 'blocker' is defensible because an (e)(5) failure goes to section 502(n) misbranding.
- Locator verified: the quoted sentence appears verbatim at 21 CFR 202.1(e)(5)(iii) in the supplied source text.